CU20080028A6 - Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus - Google Patents

Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus

Info

Publication number
CU20080028A6
CU20080028A6 CU20080028A CU20080028A CU20080028A6 CU 20080028 A6 CU20080028 A6 CU 20080028A6 CU 20080028 A CU20080028 A CU 20080028A CU 20080028 A CU20080028 A CU 20080028A CU 20080028 A6 CU20080028 A6 CU 20080028A6
Authority
CU
Cuba
Prior art keywords
silico
preparation
pharmaceutical compositions
compounds obtained
chemical compounds
Prior art date
Application number
CU20080028A
Other languages
English (en)
Inventor
Cruz Osmany Guirola
Salazar Noralvis Fleitas
Galindo Vivian Huerta
Lasa Alexis Musacchio
Reyes Yuliet Mazola
Alvarez Roberto Vera
Santiago Glay Chinea
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20080028A priority Critical patent/CU20080028A6/es
Priority to JP2010547941A priority patent/JP5400067B2/ja
Priority to BRPI0908489-4A priority patent/BRPI0908489A2/pt
Priority to AU2009218960A priority patent/AU2009218960B2/en
Priority to US12/919,416 priority patent/US8722742B2/en
Priority to CN200980113787XA priority patent/CN102006865B/zh
Priority to CA2716971A priority patent/CA2716971C/en
Priority to ES09714439.8T priority patent/ES2647506T3/es
Priority to MX2010009563A priority patent/MX2010009563A/es
Priority to EP09714439.8A priority patent/EP2258356B1/en
Priority to PCT/CU2009/000002 priority patent/WO2009106019A2/es
Publication of CU20080028A6 publication Critical patent/CU20080028A6/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos químicos obtenidos in silico que contienen dos subestructuras funcionalmente distintivas de acuerdo a la fórmula [C]-[A] donde [A] es definida como ancla y corresponde a una subestructura química capaz de unirse a la proteína E del Virus Dengue; y [C] definida como cabeza, se corresponde a una subestructura química unida covalentemente a la subestructura [A], donde dicha subestructura aporta o favorece la capacidad de las moléculas de la presente invención de inhibir la infección por virus Dengue afectando, o modulando una o más de las interacciones intermoleculares que involucran a la proteína E, para la preparación de composiciones farmacéuticas.
CU20080028A 2008-02-29 2008-02-29 Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus CU20080028A6 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CU20080028A CU20080028A6 (es) 2008-02-29 2008-02-29 Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
JP2010547941A JP5400067B2 (ja) 2008-02-29 2009-02-27 デングウイルス及びその他のフラビウイルスに対して抗ウイルス活性を有する化合物
BRPI0908489-4A BRPI0908489A2 (pt) 2008-02-29 2009-02-27 uso de compostos químicos e método para desenhar compostos químicos que atenuam ou inibem a infecção pelo vírus da dengue
AU2009218960A AU2009218960B2 (en) 2008-02-29 2009-02-27 Chemical compounds having antiviral activity against dengue virus and other flaviviruses
US12/919,416 US8722742B2 (en) 2008-02-29 2009-02-27 Chemical compounds having antiviral activity against Dengue virus and other Flaviviruses
CN200980113787XA CN102006865B (zh) 2008-02-29 2009-02-27 化学化合物在制备用于减弱或抑制黄病毒属病毒感染的药物组合物中的用途
CA2716971A CA2716971C (en) 2008-02-29 2009-02-27 Chemical compounds having antiviral activity against dengue virus and other flaviviruses
ES09714439.8T ES2647506T3 (es) 2008-02-29 2009-02-27 Compuestos químicos que tienen actividad antiviral contra el virus dengue y otros flavivirus
MX2010009563A MX2010009563A (es) 2008-02-29 2009-02-27 Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
EP09714439.8A EP2258356B1 (en) 2008-02-29 2009-02-27 Chemical compounds having antiviral activity against dengue virus and other flaviviruses
PCT/CU2009/000002 WO2009106019A2 (es) 2008-02-29 2009-02-27 Compuestos quimicos con accion antiviral contra virus dengue y otros flavivirus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20080028A CU20080028A6 (es) 2008-02-29 2008-02-29 Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus

Publications (1)

Publication Number Publication Date
CU20080028A6 true CU20080028A6 (es) 2011-02-24

Family

ID=40972816

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20080028A CU20080028A6 (es) 2008-02-29 2008-02-29 Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus

Country Status (11)

Country Link
US (1) US8722742B2 (es)
EP (1) EP2258356B1 (es)
JP (1) JP5400067B2 (es)
CN (1) CN102006865B (es)
AU (1) AU2009218960B2 (es)
BR (1) BRPI0908489A2 (es)
CA (1) CA2716971C (es)
CU (1) CU20080028A6 (es)
ES (1) ES2647506T3 (es)
MX (1) MX2010009563A (es)
WO (1) WO2009106019A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518960B2 (en) 2007-05-23 2013-08-27 Siga Technologies, Inc. Antiviral drugs for treatment or prevention of dengue infection
CN102731394A (zh) * 2011-04-12 2012-10-17 中国科学院上海药物研究所 取代的喹啉-2-甲醛-苯腙类化合物及其制备方法和用途
SG11201402660YA (en) 2011-12-21 2014-10-30 Novira Therapeutics Inc Hepatitis b antiviral agents
CN103183631B (zh) * 2011-12-28 2016-08-24 天津市国际生物医药联合研究院 靛红-5-磺酰胺类衍生物及其在制备治疗非典型性肺炎的药物中的应用
US9732067B2 (en) 2012-06-20 2017-08-15 University Of Kansas Compounds and methods for activating the apoptotic arm of the unfolded protein response
CN113679717A (zh) * 2012-08-22 2021-11-23 康奈尔大学 用于抑制肌成束蛋白的方法
KR102122244B1 (ko) 2012-08-28 2020-06-15 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
CU24188B1 (es) * 2012-12-27 2016-07-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal contra el virus dengue
BR112015020242A2 (pt) 2013-02-28 2017-07-18 Janssen Sciences Ireland Uc sulfamoil-arilamidas e seu uso como medicamentos para o tratamento da hepatite b
EP2981536B1 (en) 2013-04-03 2017-06-14 Janssen Sciences Ireland UC N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN105960400B (zh) 2013-05-17 2019-05-31 爱尔兰詹森科学公司 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
SG10201805033XA (en) 2013-07-25 2018-07-30 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015059212A1 (en) 2013-10-23 2015-04-30 Janssen R&D Ireland Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
RU2702109C1 (ru) 2014-02-05 2019-10-04 Новира Терапьютикс, Инк. Комбинированная терапия для лечения инфекций вгв
AP2016009257A0 (en) 2014-02-06 2016-06-30 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
EP3107902B1 (en) 2014-02-20 2021-04-07 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Compounds and methods for inhibiting fascin
CU20140026A7 (es) * 2014-03-03 2015-11-27 Ct De Ingeniería Genética Y Biotecnología Biocubafarma Péptidos horquilla beta con propiedades antivirales contra el virus dengue
KR20170007816A (ko) * 2014-05-23 2017-01-20 에프. 호프만-라 로슈 아게 벤젠 설폰아마이드 유도체 및 RORc 조절인자로서의 이의 용도
WO2016130321A1 (en) * 2015-02-09 2016-08-18 Academia Sinica An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
BR112018071048A2 (pt) 2016-04-15 2019-05-07 Janssen Sciences Ireland Uc combinações e métodos que compreendem um inibidor da montagem de capsídeos
PT3518948T (pt) * 2016-10-03 2023-07-17 Ottawa Hospital Res Inst Composições e métodos para melhorar o crescimento, a propagração e a eficácia imunoterapêutica de oncolítica de vírus de rna oncolíticos
CN109384727B (zh) * 2017-08-10 2023-07-28 中国科学院上海药物研究所 酞嗪酮类化合物、其制备方法、药物组合物及用途
CN108299280A (zh) * 2018-01-19 2018-07-20 天津国际生物医药联合研究院 对混合谱系白血病关键蛋白具有抑制作用的靛红-5-磺酰胺类抑制剂
SG11202007097QA (en) 2018-03-14 2020-08-28 Janssen Sciences Ireland Unlimited Co Capsid assembly modulator dosing regimen
WO2019199496A1 (en) * 2018-04-12 2019-10-17 Purdue Research Foundation Benzamide antibacterial agents
TW202045499A (zh) 2019-02-22 2020-12-16 愛爾蘭商健生科學愛爾蘭無限公司 用於治療ｈｂｖ感染或ｈｂｖ誘發疾病之醯胺衍生物
MA55879A (fr) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
CN111346079B (zh) * 2020-02-24 2023-06-20 南方医科大学 细菌dna促旋酶抑制剂brd7716作为治疗和/或预防登革病毒感染的药物及其制药用途
EP4157263A4 (en) * 2020-05-26 2024-09-11 Univ Michigan Regents MITOCHONDRIAL TARGETED COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES
WO2023158708A1 (en) * 2022-02-16 2023-08-24 Denali Therapeutics Inc. Compounds, compositions, and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
CU23245A1 (es) * 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
WO2005002501A2 (en) 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) * 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
CA2701465A1 (en) * 2007-09-07 2009-03-12 Mevlabs, Inc. Formulations and devices for delivering compounds to arthropods and microorganisms within arthopods

Also Published As

Publication number Publication date
MX2010009563A (es) 2010-09-24
AU2009218960B2 (en) 2013-06-27
CN102006865A (zh) 2011-04-06
US8722742B2 (en) 2014-05-13
EP2258356B1 (en) 2017-09-27
US20110065686A1 (en) 2011-03-17
WO2009106019A3 (es) 2010-01-28
EP2258356A2 (en) 2010-12-08
BRPI0908489A2 (pt) 2018-03-27
JP2011513250A (ja) 2011-04-28
CA2716971A1 (en) 2009-09-03
CA2716971C (en) 2016-05-10
CN102006865B (zh) 2013-04-24
AU2009218960A1 (en) 2009-09-03
ES2647506T3 (es) 2017-12-21
JP5400067B2 (ja) 2014-01-29
WO2009106019A2 (es) 2009-09-03

Similar Documents

Publication Publication Date Title
CU20080028A6 (es) Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
BR112014006324B8 (pt) composição e seu uso para o tratamento de hcv
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
CY1112999T1 (el) Αναστολεις ιου ηπατιτιδας c
BR112012011100A2 (pt) compostos inibidores do vírus da hepatite, composição e uso dos mesmos
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
BR112013020042A2 (pt) inibidores de vírus da hepatite c
MA32257B1 (fr) Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.
BR112012004696B8 (pt) composto modulador da atividade de tlr, seu uso, composição farmacêutica, medicamento, kit e combinação
UY33445A (es) Un régimen de dosificación, métodos para tratar el virus de la hepatitis c, composición farmacéutica, compuesta, compuestos anti-hcv y kit
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
UY31952A (es) 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
BRPI0814252B8 (pt) composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
MX2010009738A (es) Compuestos y composiciones como moduladores de la actividad de tlr.
EA201001275A1 (ru) Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
BRPI1009637A2 (pt) composto, composição e uso de um composto
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
BRPI0908421B8 (pt) solução estável de um composto farmacêutico
BRPI0920655A2 (pt) conjugados e hpma-docetaxel ou gencitabina e usos dos mesmos
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
NO20084852L (no) MGLUR5 modulatorer V